Oxycodone is a drug prescribed to relieve moderate to severe pain. Oxycodone is in the class of opioids. It binds the opiate receptors by altering the pain perception, and response to stimuli hence decreased pain (Jennifer et al. 2016).
As a clinician, create a rapport with Ashish by explaining to him the disadvantages and consequences of high quantity consumption of the drug. Explain to him the physiology of drug addiction. In this case, oxycodone tolerance will decrease drug response. This occurs when there is repeated drug usage, and the body adjusts to the continued existence of the drug. This then results in drug resistance. It can as well interfere with brain neurons’ performance that sends and receive feedback. Ashish, therefore, ought to follow the drug prescription (Yokell et al. 2011).
Buprenorphine/naloxone is an opioid addiction agent. It is an opioid agonist. It will aid Ashish in the maintenance treatment of opioid dependence as part of a comprehensive program inclusive of counseling and psychological upkeep (Campbell & Lovell 2012).
Buprenorphine/naloxone’s trade name Suboxone. It is available as a sublingual formulation in both tablets and films. These formulations are used wholly for addiction management. The sublingual formulation is available in two, unlike forms. They are either as a combination tablet of buprenorphine and naloxone or buprenorphine only. Also, there is buccal formation as well as buprenorphine implants (Fiellin et al. 2012).
Opiates, for example, heroin, cause withdrawal symptoms a few hours following the last dose. The intensity of symptoms in an individual depends on the prescribed dosage and how soon they ceased taking the drug. The type of opiate also affects the symptoms that people experience. Short-acting opiates, for instance, heroin, can generate more severe symptoms within a shorter time-frame. In contrast, long-acting opioids, for example, methadone, can take up to 30 hours following the last dose to source a symptom. Symptoms transpire due to the body’s detoxification of the drug. General symptoms comprise diarrhea, muscle tremors, muscle and stomach aches, tension and restlessness, tachycardia, elevated body temperatures and chills, nausea and vomiting, and depression. Symptoms can either be mild or severe. They depend on the overall health of the person, inclusive of the medical conditions. Drug usage with regards to the extent and duration. The rate at which the environment is stressing and cases of the history of addiction within the family (Yokell et al. 2011).
Ashish and Ana ought to take the following steps to ease the withdrawal symptoms: Encourage hydration. Ashish should drink plenty of water because, during withdrawal, he may lose lots of bodily fluids through sweat and diarrhea. Encourage present electrolyte fluids, for example, coconut water. Due to the high consumption rate of an opiate by Ashish, he should, therefore, take meals rich in calcium, potassium, and magnesium to recover the lost nutrients. Ashish should ensure he takes hot saline baths. This will aid in soothing muscle aches and provide magnesium. Ana should monitor when Ashish takes the baths. He should not bathe in episodes of fevers. Ana should at least assist Ashish in some exercises to relieve the agitation. Exercises help in mood improvement and tension reduction as there is the release of endorphins. Due to the uncomfortable symptoms, Ashish is experiencing as a result of withdrawal, the presence of loved ones would be very crucial; for instance, Ana. This will help in mind distraction and provide relief. It is also essential to refer Ashish to groups of people experiencing the same, so he can learn what others are doing to cope with the symptoms (Fiellin et al. 2012).
Jennifer, A., Howard. S., et al. (2016). Handbook of Acute Pain Management: Pp. 82
Campbell, N., & Lovell, A. (2012). The history of the development of buprenorphine as an addiction therapeutic. Pp. 124–139.
Schackman, B., Leff, J., Polsky, D., Moore, B., Fiellin, D. (2012). Cost-effectiveness of long- term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. Pp. 669-676.
Yokell, M., Zaller, N., Green, T., & Rich, J. (2011). Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: An international review: Pp. 28–41.